๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001-2002

โœ Scribed by Russell Cohen; Don Robinson Jr.; Clark Paramore; Kathy Fraeman; Kevin Renahan; Mohan Bala


Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
234 KB
Volume
14
Category
Article
ISSN
1078-0998

No coin nor oath required. For personal study only.

โœฆ Synopsis


Background:

Recent studies suggest that inflammatory bowel disease (ibd) may share an underlying pathogenesis with other autoimmune diseases.

Methods:

Two united states data sets with patient-level medical and drug claims were used to explore the occurrence of autoimmune diseases in patients with ibd, particularly crohn's disease (cd) and ulcerative colitis (uc), with that in controls. from 2001 to 2002 ibd patients were identified using international classification of diseases, 9th revision, diagnosis codes in the ims health integrated administration claims database and the market scan commercial claims and encounters database. controls were selected by matching on sex, age, census bureau region, and length of previous medical insurance coverage. odds ratios (ors) evaluated the risk relationship between ibd patients and controls within an estimated mantel-haenszel 95% confidence interval. sensitivity analysis tested the case identification method used to select ibd patients.

Results:

The risk for ankylosing spondylitis (as) was substantially increased across both data sets: or (95% confidence interval [ci]) of 7.8 (5.6-10.8) in ims health and 5.8 (3.9-8.6) in marketscan. the risk for rheumatoid arthritis (ra) was 2.7 (2.4-3.0) and 2.1 (1.8-2.3), respectively; for multiple sclerosis (ms); the ors were 1.5 (1.2-1.9) and 1.6 (1.2-2.1), respectively. there was no increased risk for type 1 diabetes mellitus, and the results for psoriatic arthritis (psa) were inconsistent. the sensitivity analysis supported these findings.

Conclusions:

A much higher risk for ra, as, psa, and ms was observed in ibd patients compared with controls. prospective epidemiologic studies are needed to confirm these findings and explore the pathogenic mechanism of this relationship.


๐Ÿ“œ SIMILAR VOLUMES


Increased risk of vancomycin-resistant e
โœ Geoffrey C. Nguyen; Wesley Leung; Adam V. Weizman ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 85 KB ๐Ÿ‘ 2 views

Background: Vancomycin-resistant Enterococcus (VRE) infection has become an increasingly common hospital-acquired infection in U.S. hospitals. Patients with inflammatory bowel disease (IBD) frequently require hospitalization and therefore may be at increased risk of nosocomial infections. Methods:

Hospitalizations for inflammatory bowel
โœ Geoffrey C. Nguyen; Justina Sam; Sanjay K. Murthy; Gilaad G. Kaplan; Jill M. Tin ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 225 KB ๐Ÿ‘ 1 views

## Background: Inflammatory bowel disease (ibd) patients may be at increased risk for having no health insurance. our objectives were to assess the prevalence of hospitalized ibd patients without insurance in the us and to characterize predictive factors. ## Methods: We identified ibd admissions

Rising hospitalization rates for inflamm
โœ Geoffrey C. Nguyen; Anne Tuskey; Themistocles Dassopoulos; Mary L. Harris; Steve ๐Ÿ“‚ Article ๐Ÿ“… 2007 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 204 KB ๐Ÿ‘ 1 views

## Background: Recent epidemiological studies suggest that the prevalences of Crohn's disease (CD) and ulcerative colitis (UC) are increasing in the United States. We sought to determine whether nationwide rates of inflammatory bowel disease (IBD) hospitalizations have increased in response to temp

Inflammatory bowel disease-attributable
โœ K.T. Park; Dorsey Bass ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 89 KB ๐Ÿ‘ 2 views

The United States spends more for healthcare than any other country in the world. With the rising prevalence of both Crohn's disease and ulcerative colitis, inflammatory bowel disease (IBD) represents the leading chronic gastrointestinal disease with increasing healthcare expenditures in the US. IBD

QuantiFERON TB gold testing for tubercul
โœ Bashar J. Qumseya; Ashwin N. Ananthakrishnan; Sue Skaros; Michael Bonner; Mazen ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 134 KB ๐Ÿ‘ 2 views

Background: Reactivation of latent Mycobacterium tuberculosis (TB) is a rare, yet devastating infectious complication associated with anti-tumor necrosis factor alpha (TNF-a) therapy. We evaluated the performance of the QuantiFERON TB Gold test (QFT-G) for TB screening in a cohort of inflammatory bo